United States orthopedic, prosthetic and surgical appliances and supplies industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Top Orthopedic, Prosthetic And Surgical Appliances And Supplies Stocks in USA

Name: Top Orthopedic, Prosthetic And Surgical Appliances And Supplies Stocks in USA comparison snapshot
Creator: Fliar BI Prism

Five U.S.-listed orthopedic, prosthetic and surgical appliances and supplies names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderBone Biologics · 47

Strongest available pathSteris · +8.4%

Widest latest marginSteris · 11.3%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1BBLG · Nasdaq

Bone Biologics

A U.S.-listed issuer classified by the SEC in Orthopedic, Prosthetic And Surgical Appliances And Supplies

Founded 2004Boston, Massachusetts$1.7M market cap

View full Companies Radar profile

47Cautious

Snapshot price$0.61as of page date

Monthly-close return-100.0%five-year window

FY2020 revenue$1.07BBone Biologics Corp

Net margin-0.2%FY2020

P/E snapshot-0.9xone ratio, not a verdict

Prism attention0.7%share across these five

Filing track recordRevenue, USD billions

+0.0%

FY2017–FY2020 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.0%

52-week position1% through range

$0.58$4.13

News mentions218

Community mentions3partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position0/100
Capital-event signal74/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ALGN · Nasdaq

Align Technology

A U.S.-listed issuer classified by the SEC in Orthopedic, Prosthetic And Surgical Appliances And Supplies

Founded 1997WILMINGTON$11.19B market cap

View full Companies Radar profile

46Cautious

Snapshot price$157.6as of page date

Monthly-close return-77.6%five-year window

FY2025 revenue$4.04BALIGN TECHNOLOGY INC

Net margin10.2%FY2025

P/E snapshot27.3xone ratio, not a verdict

Prism attention9.2%share across these five

Filing track recordRevenue, USD billions

+2.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.5%

52-week position45% through range

$122.0$200.4

News mentions2.9K

Community mentions191partial coverage

U.S.-scope patents4563

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position14/100
Capital-event signal15/100
Innovation pulse18/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 1 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ZBH · NYSE

Zimmer Biomet

A U.S.-listed issuer classified by the SEC in Orthopedic, Prosthetic And Surgical Appliances And Supplies

Founded 1927WILMINGTON$19.25B market cap

View full Companies Radar profile

46Cautious

Snapshot price$100.9as of page date

Monthly-close return-31.9%five-year window

FY2025 revenue$8.23BZIMMER BIOMET HOLDINGS, INC.

Net margin8.6%FY2025

P/E snapshot24.5xone ratio, not a verdict

Prism attention78.1%share across these five

Filing track recordRevenue, USD billions

+5.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.2%

52-week position78% through range

$79.12$106.9

News mentions24.2K

Community mentions82partial coverage

U.S.-scope patents486

Prism InsightsWhat sits behind the readiness signal
Observed risk 6/100higher means more observed risk

Earnings signal64/100
Management stability90/100
Market position22/100
Capital-event signal35/100
Innovation pulse13/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 36 M&A involvements, 2 asset-acquisition events and 13 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4STE · NYSE

Steris

A U.S.-listed issuer classified by the SEC in Orthopedic, Prosthetic And Surgical Appliances And Supplies

Founded 1985COLUMBUS$22.79B market cap

View full Companies Radar profile

45Cautious

Snapshot price$233.8as of page date

Monthly-close return+8.4%five-year window

FY2025 revenue$5.46BSTERIS plc

Net margin11.3%FY2025

P/E snapshot28.6xone ratio, not a verdict

Prism attention9.6%share across these five

Filing track recordRevenue, USD billions

+75.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.1%

52-week position52% through range

$195.1$269.4

News mentions3.0K

Community mentions112partial coverage

U.S.-scope patents1104

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position26/100
Capital-event signal20/100
Innovation pulse8/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 19 M&A involvements, 13 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5ENOV · NYSE

Enovis

A U.S.-listed issuer classified by the SEC in Orthopedic, Prosthetic And Surgical Appliances And Supplies

Founded 2022Wilmington, Delaware$1.44B market cap

View full Companies Radar profile

35Cautious

Snapshot price$24.90as of page date

Monthly-close return-70.1%five-year window

FY2025 revenue$2.25BEnovis CORP

Net margin-52.7%FY2025

P/E snapshot6.2xone ratio, not a verdict

Prism attention2.4%share across these five

Filing track recordRevenue, USD billions

-41.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -12.6%

52-week position38% through range

$19.14$34.28

News mentions739

Community mentions9partial coverage

U.S.-scope patents219

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal48/100
Management stability90/100
Market position14/100
Capital-event signal10/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Steris

+8.4%

Zimmer Biomet

-31.9%

Enovis

-70.1%

Align Technology

-77.6%

Bone Biologics

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Zimmer Biomet

$8.23B

Steris

$5.46B

Align Technology

$4.04B

Enovis

$2.25B

Bone Biologics

$1.07B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Steris

11.3%

Align Technology

10.2%

Zimmer Biomet

8.6%

Bone Biologics

-0.2%

Enovis

-52.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Zimmer Biomet

78.1%

Steris

9.6%

Align Technology

9.2%

Enovis

2.4%

Bone Biologics

0.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized orthopedic, prosthetic and surgical appliances and supplies news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Zimmer Biomet leads the conversation

It holds 78.1% of measured orthopedic, prosthetic and surgical appliances and supplies news attention and also carries the basket's largest revenue base at $8.23B.

Price path

Steris leads the available price paths

Its monthly-close return is +8.4% for the five-year window. At the other end, Bone Biologics is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Steris has the widest latest margin

Its FY2025 net margin is 11.3%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Bone Biologics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -0.9x while its five-year window price return is -100.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ALGN

Align Technology

2,866available Prism news records

Prism top themes

Price action & investor response

160

Earnings & financial performance

Macro demand & rates

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-4.8%393 latest 12m vs 413 prior 12m

Machine-classified coverage tone

89.8% positive+6.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

dental scaler 44stock performance 403d dental printing 37dental x-ray machine 323d printer software 29orthodontic adjustments 28cad/cam dentistry 28orthodontic headgear 27

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-18 · trend and themes shown through 2026-06

Areas of research · ZBH

Zimmer Biomet

24,225available Prism news records

Prism top themes

Price action & investor response

188

Earnings & financial performance

187

Leadership & governance

113

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-25.8%2,017 latest 12m vs 2,718 prior 12m

Machine-classified coverage tone

82.0% positive-2.2 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

musical animation 101animated song sequences 101hip replacement surgery 60nfl team lineups 55nfl player stats 53nfl starting lineup 51robotic surgery 45earnings report 44

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-07-22 · trend and themes shown through 2026-07

Areas of research · STE

Steris

2,970available Prism news records

Prism top themes

Price action & investor response

154

Capital allocation & transactions

115

Earnings & financial performance

Macro demand & rates

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+59.4%647 latest 12m vs 406 prior 12m

Machine-classified coverage tone

93.2% positive+1.4 pp vs preceding four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

investment deal 82sterilization pouches 46uv sterilizer 45stock performance 43chemical sterilants 42dry heat sterilizer 29quarterly results 24hydrogen peroxide sterilizer 23

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-23–2026-07-16 · trend and themes shown through 2026-07

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

ALGN

Align Technology

191 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 191 records remained after filtering.

ZBH

Zimmer Biomet

82 mentions

Stock and valuation

Workplace and hiring

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 82 records remained after filtering.

STE

Steris

112 mentions

Products, pricing and logistics

Workplace and hiring

Stock and valuation

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 112 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

BBLG

Bone Biologics

through 2026-01-05

Leadership changes 6Company announcements 4Listing / IPO 2

2026-01-05
Company announcements
Bone Biologics received confirmation that the shelf life of its rhNELL-1 differentiated bone growth factor product has been extended to 24 months, delivering on previously-communicated forecasts.
2024-10-21
Leadership changes
Bone Biologics Corporation (“Bone Biologics” or the “Company”) announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately.
2023-06-15
Listing / IPO
Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ALGN

Align Technology

through 2026-04-30

Earnings releases 30Leadership changes 18Lawsuits 4M&A 4Company announcements 2

2026-04-30
Earnings releases
Total revenue was $1.04 billion, up 6.2% year over year, which Hogan attributed “primarily by high Clear Aligner volumes and increased ASPs.”
2026-03-19
M&A
Elliott Investment Management has acquired a significant stake in Align Technology Inc. (NASDAQ: ALGN), the company behind the widely popular Invisalign teeth-straightening system, according to a Bloomberg report.
2025-08-22
Company announcements
The company has begun plans to produce face shields and nasal swabs for COVID‑19 testing kits to donate to hospitals and health workers.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ZBH

Zimmer Biomet

through 2026-05-04

Earnings releases 62Leadership changes 30M&A 17Company announcements 5Business contracts 4

2026-05-04
Company announcements
Suketu Upadhyay, CFO and EVP of Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global medical technology provider, departed the company on April 28 for a new professional opportunity.
2026-04-29
Earnings releases
Zimmer Biomet reported 1Q26 orthopedic sales of $2 billion, up 9.3% compared to the first quarter of 2025.
2026-04-28
Leadership changes
the company has named Paul Stellato, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer, while the company conducts an internal and external search to identify a permanent successor.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

STE

Steris

through 2026-02-04

Earnings releases 25Asset acquisitions 12Company announcements 10Leadership changes 5M&A 3

2026-02-04
Earnings releases
Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025.
2026-01-28
Company announcements
STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share.
2025-12-01
M&A
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ENOV

Enovis

through 2025-12-03

Earnings releases 21Leadership changes 11M&A 5Asset acquisitions 2Company announcements 1

2025-12-03
Leadership changes
Christopher M. Hix, Chief Financial Officer (Retired), Enovis Corporation
2025-11-13
Earnings releases
Revenue: $548.9 million vs analyst estimates of $537.6 million (8.6% year-on-year growth, 2.1% beat)
2024-01-03
M&A
Enovis Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. ("Lima")…

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Orthopedic, Prosthetic And Surgical Appliances And Supplies Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary orthopedic, prosthetic and surgical appliances and supplies news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

orthopedic prosthetics market

6 sources67.5% extraction confidence

2024 extracted base$2.14B–$3.72B

2034 extracted forecast$3.91B–$3.91B

Implied source CAGR5.0%

increasing number of trauma casesaccidental injuriesgrowing popularity of customized orthopedic prosthetics

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, North America, China, United Kingdom. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Orthopedic, Prosthetic And Surgical Appliances And Supplies news pulse

13,275available Prism news records

Latest 12m volume-15.6%5057 vs 5991 records

Positive classified tone77.4%-6.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching appliance, orthopedic, prosthetic, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

brain tumor surgical interventions

1,757

orthopedic supports and prosthetics

1,150

orthopedic hospitals & joint replacement centers

959

neuroblastoma in children

947

medical robotics and surgical assistants

903

surgical instrument accessories

897

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

orthopedic specialty facility 679robotic surgery 664robot-assisted surgery 655orthopedic hospital 614specialty surgery center 601orthopedic surgery center 586telesurgery robots 575operative care facility 553

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of trauma cases

6 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

brain tumor surgical interventions

1,757 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

1,427 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

high cost of prosthetics

87 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

-15.6% news volume

The latest 12 months contain 5,057 matched records versus 5,991 in the previous window.

Available Prism coverage through 2026-05-04

Caution · sentiment

Classified tone is not demand

77.4% positive · -6.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-04; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 3842 (Orthopedic, Prosthetic And Surgical Appliances And Supplies). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Orthopedic, Prosthetic And Surgical Appliances And Supplies Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Bone Biologics leads the readiness ranking

Its Prism readiness score is 47/100, the highest in this five-company comparison.

Open Bone Biologics in Companies Radar

Scale and margin leadership sit with Zimmer Biomet and Steris

Zimmer Biomet has the largest displayed latest revenue at $8.23B; Steris has the widest displayed latest margin at 11.3%.

Open Zimmer Biomet in Companies Radar Open Steris in Companies Radar

Comparisons

Strongest versus weakest available price path

Steris is +8.4% for its five-year window; Bone Biologics is -100.0% for its five-year window.

Open Steris in Companies Radar Open Bone Biologics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $8.23B for Zimmer Biomet to $1.07B for Bone Biologics. Entity and filing-period labels remain visible on the company cards.

Open Zimmer Biomet in Companies Radar Open Bone Biologics in Companies Radar

Anomalies

Bone Biologics has the widest attention-readiness rank gap

It ranks #5 by measured news attention (0.7%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Bone Biologics in Companies Radar

Align Technology shows a price-operating divergence to inspect

Its displayed filing-revenue change is +2.1% while its available monthly-close return is -77.6%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Align Technology in Companies Radar

Explanations

Attention measures coverage volume, not quality

Zimmer Biomet's 78.1% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Zimmer Biomet in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Bone Biologics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 47/100 score.

Open Bone Biologics in Companies Radar

Stress-test the largest divergence before forming a view

Compare Align Technology's profile with Steris's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Align Technology in Companies Radar Open Steris in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.